Aetiopathogenesis of ischemic stroke in rheumatoid arthritis: a case series study from tertiary care centre of South India
DOI:
https://doi.org/10.18203/2320-6012.ijrms20223655Keywords:
Stroke, Rheumatoid, Cerebral, Vasculitis, Aetiopathogensis, ImmunotherapyAbstract
Stroke is a major health concern worldwide. Published meta-analyses showed significant higher risk of ischemic and hemorrhagic stroke in patients with rheumatoid arthritis (RA) compared to the general population. Major etiopathogenesis of ischemic stroke in RA is non-atherosclerotic vasculopathy. Here the authors described varied aetiopathogensis of ischemic stroke in patients with RA which had been seldom reported in the literature. It was one of the first case series which threw light in this genre. Observational, prospective case series study was conducted over a period of one year. Amongst four cases presenting as an ischemic stroke with co-existing RA; each patient had a medium or small vessel vasculopathy, which had never been described earlier. Case 1 had cardio embolic source plus large vessel vasculopathy, case 2 had intracranial non-atherosclerosis vasculopathy; case 3 had secondary Moya-Moya disease; case 4 had both intracranial and extra cranial vasculopathy. Underlying aetiopathogensis of stroke in patients with RA can be attributed to insufficient cardiovascular treatment (well described in the literature) and vasculopathy of extracranial and intracranial vessels and secondary Moyamoya disease due to RA. Thorough evaluation is needed to prevent recurrence of stroke. The treatment strategy in these patients are immunotherapy apart from the conventional therapy with antiplatelet and statins.
References
Wiseman SJ, Ralston SH, Wardlaw JM. Cerebrovascular disease in rheumatic diseases: a systematic review and meta-analysis. Stroke. 2016;47(4):943-50.
Rawla P. Cardiac and vascular complications in rheumatoid arthritis. Reumatologia. 2019;57(1):27-36.
Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 1993;24(1):35-41.
Sofat N, Malik O, Higgens CS. Neurological involvement in patients with rheumatic disease. QJM. 2006;99:69-79.
Watts RA, Mooney J, Lane SE, Scott DGI. Rheumatoid vasculitis: becoming extinct? Rheumatology. 2004;43(7):920-3.
Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17-28.
Lee DH, Sheen SH, Lee DG, Jang J, Lee DC, Shin S, et al. Association between ischemic stroke and seropositive rheumatoid arthritis in Korea: A nationwide longitudinal cohort study. PLoS One. 2021;16(5):0251851.
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360-72.
Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322(4):315-25.
Mease PJ, Stryker S, Liu M, Salim B, Rebello S, Gharaibeh M, et al. Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry. Arthritis Res Ther. 2021;23(1):236.
